Ab­b­Vie rolls up an­oth­er big win for elagolix as the prospec­tive block­buster sweeps end­points in lat­est PhI­II

Al­ready on the fast pri­or­i­ty track at the FDA with their ap­pli­ca­tion to start sell­ing elagolix for en­dometrio­sis, Ab­b­Vie $AB­BV said to­day that the drug al­so came through with fly­ing col­ors in the first of two piv­otal tri­als for uter­ine fi­broids.

This drug has al­ready been tapped as a like­ly block­buster for Ab­b­Vie, one of sev­er­al top drugs in its late-stage pipeline as the com­pa­ny looks to add to a com­mer­cial port­fo­lio dom­i­nat­ed by Hu­mi­ra.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.